We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.12B
1-Year Est. Return 144%
This Fund
S&P 500
This Quarter Est. Return
+8.63%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.12B
AUM Growth
+$30M
Cap. Flow
-$55.4M
Cap. Flow %
-1.78%
Top 10 Hldgs %
52.44%
Holding
76
New
7
Increased
18
Reduced
21
Closed
10

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$114M
2
JBIO
Jade Biosciences
JBIO
+$85.4M
3
AXSM icon
Axsome Therapeutics
AXSM
+$84.9M
4
PCVX icon
Vaxcyte
PCVX
+$45.9M
5
APLS
Apellis Pharmaceuticals
APLS
+$37M

Top Sells

Rank Stock Value
1
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$264M
2
BBIO icon
BridgeBio Pharma
BBIO
+$69.1M
3
GH icon
Guardant Health
GH
+$53.3M
4
AMGN icon
Amgen
AMGN
+$35.2M
5
EWTX icon
Edgewise Therapeutics
EWTX
+$30.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RAPT
51
DELISTED
RAPT Therapeutics
RAPT
$6.01M 0.19%
751,422
-1
-0% -$8
CNTX icon
52
Context Therapeutics
CNTX
$56.7M
$4.86M 0.16%
7,419,355
– –
PLRX icon
53
Pliant Therapeutics
PLRX
$65M
$4.58M 0.15%
3,947,807
-1,451,874
-27% -$2.05M
SRPT icon
54
Sarepta Therapeutics
SRPT
$1.64B
$4.44M 0.14%
259,800
-639,931
-71% -$27.3M
XNCR icon
55
Xencor
XNCR
$1.45B
$4.32M 0.14%
549,439
– –
INO icon
56
Inovio Pharmaceuticals
INO
$85.6M
$4.03M 0.13%
1,981,370
-1,137,792
-36% -$2.18M
KRRO icon
57
Korro Bio
KRRO
$145M
$3.47M 0.11%
277,966
-596,648
-68% -$8.59M
IMA
58
ImageneBio Inc
IMA
$63.4M
$3.37M 0.11%
209,626
– –
SYRE icon
59
Spyre Therapeutics
SYRE
$8.5B
$3.28M 0.11%
219,015
– –
ALGS icon
60
Aligos Therapeutics
ALGS
$26.3M
$3.2M 0.1%
444,110
– –
AVTX icon
61
Avalo Therapeutics
AVTX
$1.01B
$2.83M 0.09%
567,103
-292,773
-34% -$1.37M
ZURA icon
62
Zura Bio
ZURA
$504M
$1.81M 0.06%
1,727,562
-1,556,221
-47% -$1.86M
CLYM
63
Climb Bio
CLYM
$693M
$1.29M 0.04%
1,040,115
– –
SEPN
64
Septerna Inc
SEPN
$1.51B
$1.29M 0.04%
121,716
-1,791,213
-94% -$14.8M
RAPP
65
Rapport Therapeutics
RAPP
$1.96B
$1.12M 0.04%
98,237
-359,319
-79% -$3.81M
OKUR
66
OnKure Therapeutics
OKUR
$160M
$431K 0.01%
180,510
-343,479
-66% -$901K
ALLK
67
DELISTED
Allakos
ALLK
– –
-7,232,701
Closed -$1.65M
AMGN icon
68
Amgen
AMGN
$209B
– –
-113,035
Closed -$35.2M
BEAM icon
69
Beam Therapeutics
BEAM
$2.68B
– –
-315,765
Closed -$6.17M
DYN icon
70
Dyne Therapeutics
DYN
$4.15B
– –
-2,000,000
Closed -$20.9M
EWTX icon
71
Edgewise Therapeutics
EWTX
$4.28B
– –
-1,400,000
Closed -$30.8M
LKFT
72
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
– –
-741,068
Closed -$18.6M
NGNE icon
73
Neurogene
NGNE
$672M
– –
-116,660
Closed -$1.37M
RGLS
74
DELISTED
Regulus Therapeutics
RGLS
– –
-3,262,564
Closed -$5.71M
SAGE
75
DELISTED
Sage Therapeutics
SAGE
– –
-2,038,845
Closed -$16.2M
1 2
3
4

Similar funds

AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
B
Barings Charlotte, North Carolina $6.19B AUM 16.5% 1-Year Est. Return

Deep Track Capital's Q2 2025 Portfolio in Review

As of Q2 2025, Deep Track Capital held 76 positions worth $3.12B, up 0.97% from $3.09B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Deep Track Capital's Q2 2025 filing shows 7 new, 18 increased, 21 reduced and 10 closed positions. Its largest new stake was Jade Biosciences: 2,509,301 shares worth $25.1M. The largest sale was Intra-Cellular Therapies Inc., an estimated $264M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

  • Deep Track Capital's largest Q2 2025 buy was Jade Biosciences: 2,509,301 shares worth $25.1M.
  • Deep Track Capital added most to Insmed in Q2 2025, an estimated $114M increase.
  • Deep Track Capital's biggest Q2 2025 reduction was BridgeBio Pharma, cutting an estimated $69.1M.
  • Deep Track Capital fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $264M.
  • Deep Track Capital's ten largest holdings make up 52% of its $3.12B portfolio in Q2 2025.
  • Deep Track Capital opened 7 new positions and closed 10 in Q2 2025.
  • Deep Track Capital's portfolio value rose 0.97% quarter-over-quarter to $3.12B.

Based on Deep Track Capital's 13F filing for Q2 2025, filed 14 Aug 2025.